View this email in your browser

FALL 2019

The following studies are open for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.

For more information or questions about a study, please email or call

We look forward to serving your patients.

Robert A. Winn, MD
Director, University of Illinois Cancer Center
Associate Vice Chancellor for Community Based Practice
John H. Stewart, IV, MD, MBA
Associate Director for Clinical Sciences
Physician Executive, Oncology Service Line
Browse our list of enrolling clinical trials here




UI Cancer Center Investigator Initiated Clinical Trials
Below are unique UI Cancer Center clinical trials designed by our faculty which are currently enrolling patients (click study title for more information):
Breast Cancer
Phase 2 Trial Of Neoadjuvant Weekly Carboplatin Plus Paclitaxel Followed By Doxorubicin And Cyclophosphamide In Triple Negative Breast Cancer (BRE-01)

PI: Kent Hoskins, MD
Hematologic Malignancies
Phase Ib Study of the Safety and Efficacy Of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia (BTCRC-AML17-113)

PI: John Quigley, MD
UI Cancer Center Clinical Trial Highlights
Breast Cancer
Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers (BTCRC-BRE18-337)

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (NRG-BR004)

PI: Oana Danciu, MD
Gastrointestinal Cancer
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (S1815)

PI: Neeta Venepalli, MD
Genitourinary Cancer
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients With Muscle-Invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations (A031701)

PI: Ardaman Shergill, MD
Hematologic Malignancies
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma (BGB-3111-212)

PI: John Galvin, MD
Lung Cancer
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC LUN17-139)

Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial (NRG-LU002)

PI: Lawrence Feldman, MD
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (AFT-28, CANVAS Trial)

PI: Lawrence Feldman, MD

Dr. Tapas Das Gupta Cancer Research Symposium 2019
Immuno-oncology: Opportunities to Improve Cancer Care for All Patients

October 16 • 9:00 am - 2:30 pm
UIC Student Center West, Thompson Rooms, 2nd floor
828 S. Wolcott Ave. + Google Map

Find out more »
Use password gupta2019 to register
RSVP here

Leniel Scott 
Patient Brigade Member
University of Illinois Cancer Center
Monica Bertagnolli, MD, FACP, FASCO
Past President, American Society of Clinical Oncology (ASCO);
Professor of Surgery, Harvard Medical School;
Chief, Division of Surgical Oncology, Brigham and Women’s Hospital; Member, Dana-Farber Cancer Institute.
Nita Ahuja, MD, MBA
William H. Carmalt Professor of Surgery, Yale School of Medicine; Chair, Department of Surgery; Chief of Surgery, Yale New Haven Hospital
Shelley Hwang, MD, MPH
Mary and Deryl Hart Professor of Surgery, Duke School of Medicine

Dr. Gary Kruh Cancer Research Symposium 2020

April 15, 2020 • 8:00 am - 5:00 pm
UIC Student Center West, Thompson Rooms, 2nd floor
828 S. Wolcott Ave. + Google Map

This annual event, named for former University of Illinois Cancer Center Director Dr. Gary Kruh, brings together cancer researchers, faculty and students to learn more about the latest advancements in cancer research. A student poster competition will also be held. Lunch will be provided. Speaker and event details to come.

Find out more »

The University of Illinois Cancer Center is comprised of physicians and cancer researchers dedicated to pursuing health equity; working with the community in developing research and treatment options; and studying cancer disparities. We are part of the University of Illinois at Chicago and University of Illinois Hospital and Health Sciences System.

Contact us to find out more information or refer a patient.
Copyright © University of Illinois Cancer Center. All rights reserved.

Our mailing address is:
818 S. Wolcott Ave. Chicago, IL 60622

Want to change how you receive these emails?
Unsubscribe from this list.